Phenixfin Corporation · NASDAQ:PFX
Phenixfin — Medley Capital — Q2 2013 Earnings Presentation
11 slides from Phenixfin's earnings presentation, May 2013
Slide 1: Quarter Ended March 31, 2013 Investor Presentation
Quarter Ended March 31, 2013 Investor Presentation
Slide 2: Important Notice
Important Notice This presentation contains “forward looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to risks and uncertainties. Actual outcomes and results could differ materially from those suggested by this presentation du
Slide 3: Financial & Portfolio Highlights
Financial & Portfolio Highlights Financial Highlights Q2-13 Q1-13 Q4-12 Q3-12 Q2-12 Net investment income per share $ 0.36 $ 0.39 $ 0.36 $ 0.36 $ 0.31 Net realized g gains ((losses)) 0.01 0.01 ((0.01)) - - Net unrealized gains (losses) 0.03 (0.01) 0.02 (0.08) 0.03 Net income per share 0.40 0.39 0.37
Slide 4: Select Financial & Portfolio Information
Select Financial & Portfolio Information As of and for the Three Months Ended (dollars in millions, except per share data) 3/31/2013 12/31/2012 9/30/2012 6/30/2012 3/31/2012 Net investment income per share - basic & diluted $ 0.36 $ 0.39 $ 0.36 $ 0.36 $ 0.31 Net realized and unrealized gains per sha
Slide 5: Balance Sheet
Balance Sheet (dollars in thousands, except per share data) 3/31/2013 12/31/2012 9/30/2012 6/30/2012 3/31/2012 ASSETS (Unaudited) (Unaudited) (Audited) (Unaudited) (Unaudited) Investments at fair value Non-control/non-affiliate investments $ 585,282 $ 512,261 $ 393,741 $ 355,035 $ 260,364 Affiliate
Slide 6: Portfolio by Issuer as of March 31, 2013
1 Portfolio by Issuer as of March 31, 2013 Cash and Cash Equivalents RCS Management Corporation 1% 1% 1% 1% 1% 1% 1% 1% 5% 1% 1% ARBOC Specialty Vehicles LLC Harrison Gypsum LLC 1% 4% 1% Water Capital USA, Inc. U.S. Well Services LLC 1% 1% 4% 1% Calloway Laboratories, Inc. Cenegenics LLC 1% Reddy Ic
Slide 7: Investment Portfolio as of March 31, 2013
Investment Portfolio as of March 31, 2013 1 Asset Class Industry 5% 1% 1%1% 1% 1% 1% 11% 2% 2% 2% 4% 9% 4% 4% 33% 8% 4% 5% 61% 7% 5% 5% 7% 5% 6% 5% Senior Secured 1st Lien Personal and Nondurable Consumer Products (Manufacturing Only) Healthcare, Education and Childcare Mining, Steel, Iron and Nonpr
Slide 8: Performance Overview
Performance Overview Consistent quarterly dividend ($0.36 for quarter ending 3/31/13) Diversified portfolio with no assets on non-accrual and a weighted average loan-to-value (th (through h MCC’s MCC’ d debt) bt) off 54 54.7% 7% 13.9% portfolio yield as of 3/31/131 FY Q2 2013 gross investmen
Slide 9: Performance Since IPO
Performance Since IPO Dividend Growth Portfolio Growth $0.40 $700.0 $0.35 $0.36 $0.36 $0.36 $0.36 $600.0 $594 $0.30 $0.31 $500 0 $500.0 $521 $0.28 ($ millions) $0.25 $0.25 $400.0 $402 $0.20 $0.21 $363 $300.0 $306 $0.15 $0 16 $0.16 $249 $200.0 $0.10 $199 $145 $0.05 $100.0 $105 $85 $0.00 $0.0 Quarterl
Slide 10: Transaction & Backlog Summary
Transaction & Backlog Summary 1 2 Deal Sector Security $Amount Fixed/Floating Tenor Yield Closed in Q1 FY13 Calloway Laboratories, Inc. Healthcare, Education and Childcare Senior - 1st lien $1.7 Fixed 1.8 years 14.1% RCS Management Corporation Diversified/Conglomerate Service Senior - 2nd lien 6.0 F
Slide 11: Corporate Information
Corporate Information Board of Directors Corporate Officers Research Coverage Corporate Counsel BROOK TAUBE BROOK TAUBE BB&T CAPITAL MARKETS SUTHERLAND ASBIL & BRENNAN Chairman & Chief Executive Officer Chairman & Chief Executive Officer Vernon Plack - (804)-780-3257 LLP Washington, DC ANDREW FENTRE